ArticleCancer medicine2026

Survival Outcomes and Sensitivity of PARP Inhibitors in Platinum-Sensitive Ovarian Cancer: A Retrospective Study.

Xiu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.